Director, Cancer Genetics, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
During his graduate training at the University of Wisconsin-Madison, Dr. Haigis studied the somatic genetics of intestinal tumor initiation under the guidance of Dr. William Dove. In his post-doctoral work, Dr. Haigis studied the oncogenic properties of the RAS GTPases in the laboratory of Dr. Tyler Jacks in the Massachusetts Institute of Technology Center for Cancer Research (now the David H. Koch Institute for Integrative Cancer Research).
Contact: khaigis at bidmc dot harvard dot edu
Instructor in Medicine
B.S. in Biology, Sookmyung Women's University (2001)
M.S. in Biology, Sookmyung Women's University (2003)
Ph.D. in Biology (Genomics), Sookmyung Women's University (2007)
Research Topic: Regulation of Ras oncogenicity by post translational modification
Research Interests: Cancer biology, cell biology, posttranslational modification, cancer mouse model, CRISPR
Contact: myang3 at bidmc dot harvard dot edu
B.Sc. in Biology, Oviedo University, Spain (2006)
M.Sc. in Biomedicine, Barcelona University, Spain (2008)
Ph.D. in Biomedicine, Barcelona University-Vall d'Hebron Research Institute, Spain (2013)
Research Topic: Identification and translational validation of novel therapeutic targets for Inflammatory Bowel Diseases.
Research Interests: mucosal immunology, systems biology, kinase signaling networks.
Inflammatory bowel disease (IBD) describes a related group of incurable chronic inflammatory disorders characterized by the uncontrolled inflammation of the gastrointestinal tract. Despite the breakthrough of biological treatments, such as antibodies targeting tumor necrosis factor-alpha (TNF-a), the a4b7 integrin, and the cytokines IL-12 and IL-23, only 10 to 30% respond to these treatments and 23-46% of them develop resistance over time. Critically, it is currently impossible to predict whether a patient will respond efficiently to the treatment or if he/she will develop resistance over time.
The discipline of systems biology is based on the premise that most biological problems cannot be explained by looking at just one gene or protein in isolation, but instead require the analysis of changes in global regulatory networks. Particularly for diseases such as IBD – which results from complex interactions between numerous genes, pathways, and cell types – the need for an approach that accounts for biological complexity is especially important. Therefore, in vivo systems biology is a particularly well-suited approach for understanding highly complex diseases such as chronic colitis and for unraveling the mechanisms of the pathology that may lead to the discovery of new therapeutic opportunities.
In the Haigis lab, we apply a systems biology approaches and sophisticated computational methods on multi-omics data to identify novel biomarkers and therapeutic opportunities for IBD patients.
B.S. in Biology, UNC Asheville (2009)
M.S. in Molecular and Structural Biochemistry, NC State (2012)
Ph.D. in Chemistry and Chemical Biology, Northeastern University (2015)
Research Topic: Rare oncogenic mutations in K-Ras colorectal cancers
Research Interests: Models of cancer, oncogenic mutants of Ras, signal transduction, enzyme structure and kinetics
Contact: cwjohnso at bidmc dot harvard dot edu
B.S. in Biomedical Science, University of Marburg, Germany (2010)
M.S. in Biomedical Science, University of Groningen, The Netherlands (2012)
Ph.D. in Cancer Biology, University of Dundee, UK (2016)
Research Topic: Analysis of proteome-wide changes in KRas-mutant cells and tissue by mass spectrometry (Co-advised by Steven Gygi, HMS)
Research Interests: Cancer biology, cell biology, proteomics
Title: Tissue-specific oncogenic activity of KRas.
Oncogenic KRAS mutations occur frequently in some human cancers (e.g. pancreas, colon, lung), but are rarely detected in other cancer types (e.g. liver, kidney, brain). Based on this and other observations we hypothesize that some tissues are sensitive to the oncogenic activity of mutant KRas whereas other tissues are resistant. To identify the tissue-specific mechanisms underlying KRas sensitivity and resistance I am measuring the effects of mutant KRas expression on the (phospho-)proteome by mass spectrometry in a variety of tissues from genetically engineered mice.
In addition, I am using proximity labeling and AP-MS to better understand how post-translational modifications and the interactome of KRas contribute to its distinct signaling outputs in different tissue contexts.Contact: opopow at bidmc dot harvard dot edu
B.S. in Mathematics, Case Western Reserve University (2013)
Ph.D. in Systems Biology and Bioinformatics, Case Western Reserve University (2016)
Research Topic: Computational translation of insights from mouse models and cell lines to human in vivo biology in inflammatory bowel disease and cancer (Co-advised by Douglas Lauffenburger at MIT).
Research Interests: Computational biology, network analysis, machine learning, systems biology, and precision medicine.
Contact: dkb50 at mit dot edu
B.S. in Biological Engineering, Cornell University (2010)
M.Eng in Biomedical and Tissue engineering, Cornell University (2011)
Ph.D. in Cell and Developmental Biology, Vanderbilt University (2017)
Research Topic: Analysis of immune system deregulation in autoimmune and inflammatory disease
Research Interests: Immunology, Systems Biology, Extracellular matrix signaling (co-advised by Douglas Lauffenburger, MIT)
Contact: astarch at mit dot edu
B.S. in Applied Mathematics, Northwestern University, Evanston, IL (2011)
B.S. in Biomedical Engineering, Northwestern University, Evanston, IL (2011)
M.Phil. in Physics, University of Cambridge, UK (2012)
Research Topic: In vivo systems biology of neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. (Co-advised by Douglas Lauffenburger, MIT)
Research Interests: Systems Biology, Neurodegenerative Diseases, Alzheimer's Disease, Frontotemporal Dementia, Computational Analysis
Contact: sdstrass at mit dot edu
B.A. in Biology, Specialization in Cell Biology, Molecular Biology and Genetics, Boston University (2011)
B.A. in French Language and Literature, Boston University (2011)
Research Topic: Characterization of K-RasG13D as a unique activating mutation in cell line and murine models of colorectal cancer.
Research Interests: Broadly in cancer biology, specifically in cancer genetics, cancer immunology, and translational research for colorectal cancer
Contact: yijanglin at g dot harvard dot edu
B.S. in Cell and Developmental Biology, University of California Irvine (2013)
Research Topic: Characterization of K-Ras mutants in colorectal cancer; regulation of Ras acetylation
Research Interests: Cancer biology, signaling pathways, mechanism, gene regulation
Contact: ssheth at g dot harvard dot edu
B.A. in Biology, Carleton College (2016)
Research Topic: Investigating the role of Ras in colorectal cancer and intestinal epithelium regeneration. Characterizing Ras alleles competition within different genetic backgrounds and disease contexts.
Research Interests: Cancer signaling, tissue regeneration, mechanism of cancer invasion and metastasis
I am working on elucidating the interplay between K-Ras signaling activation and downstream miRNAs. This is done in the context of colon homeostasis and mutant K-Ras-driven colorectal cancer in GEMMs, focusing on physiological interactions between miRNAs and target mRNAs. Using a multi-omics approach, I hope to uncover a network of miRNA-mediated regulation of gene expressions downstream of K-Ras pathway.
Contact: bshui at bidmc dot harvard dot edu
B.S. in Biochemistry & Molecular Biology, University of California, Irvine (2017)
B.S. in Chemistry, University of California, Irvine (2017)
Research Topic: somatic mutational evolution in cancer; tissue specificity of cancer driving mutations (Co-advised by Peter Park, HMS)
Research Interest: cancer biology, pathway analysis, genetic interactions of mutations
I’m studying the effects of the various KRAS mutations on the behavior and mutational landscape of cancers. I’m using computational methods to uncover patterns of dysregulation unique to each KRAS variant. Also, I’m interested in how KRASmutations are highly prevalent among a select few cancer types, whilst vanishingly rare in most others.
Contact: jhcook at g dot harvard dot edu
Education: B.A. in Biology (Biochemistry Emphasis), University of California, Santa Barbara (2016)
Research Topic: Investigating novel methods to perturb the immune system in the treatment of Ras-driven cancers
Research Interest: Cancer immunology, therapeutic development, genetic screens, mutation allele analysis, tumor microenvironment
Contact: kdervishi at g dot harvard dot edu
Education: B.S in Mathematics of Computation, University of California, Los Angeles (2015)
Research Topic: Characterizing oncogenic properties of different KRAS mutants in colorectal cancer (Co-advised by Franziska Michor, DFCI)
Research Interest: Cancer evolution, mechanisms of resistance and metastasis
Contact: sstein at g dot harvard dot edu
Education: B.A. in Integrative Biology, Skidmore College (2017)
I am currently working with Dr. Moon Hee Yang on characterizing K104 mutant Kras in the context of normal colon epithelium and colorectal cancer. We are also using orthotopic injection mouse models of colorectal cancer to compare Kras mutant alleles at the cellular level.
Contact: bhunt3 at bidmc dot harvard dot edu
Education: B.S. in Biochemistry, Ithaca College (2015)
Research Interests: cancer biology, signaling pathways, molecular mechanisms of autoimmunity and precision medicine
Contact: amerced at bidmc dot harvard dot edu
B.S. in Biology, Sookmyung Women's University (2003)
M.S. in Bioinformatics, Sookmyung Women's University (2005)
Contact: hlee11 at bidmc dot harvard dot edu